Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) Tablet in Adult Patients With Advanced Cholangiocarcinoma

NCT04919642 is registered in ClinicalTrials.gov with TransThera Sciences (Nanjing), Inc. as lead sponsor.

NCT NCT04919642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04919642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) Tablet in Adult Patients With Advanced Cholangiocarcinoma
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 7, 2021
Completion date
February 28, 2024
Enrollment
55 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, fgfr1 alteration, fgfr2 fusion, fgfr2 gene mutation, fgfr3 alteration